CD4 and cranioectodermal dysplasia: In the last 20 years, commercial drug development for CeD has accelerated, and includes investigational products repurposed from other diseases as well as novel antigen-specific immunotherapies applicable only to CeD but instructive for other diseases driven by antigen-specific CD4+ T cells.